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Abstract: Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been 
approved for the detection of prostate cancer (PCa) in patients with elevated prostate-specific-
antigen following prior treatment. This review and meta-analysis aimed to investigate the 
diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography 
(PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed 
including several databases, using the following terms: “FACBC”/“fluciclovine” AND “prostate 
cancer”/“prostate” AND “PET”/“Positron Emission Tomography”. Fifteen and 9 studies were 
included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the 
pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 
75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. 
At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of 
primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% 
vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-
prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be 
promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies 
to evaluate its utility in clinical routine are mandatory.  
Keywords: prostate cancer; 18F-FACBC; PET/CT; recurrence; meta-analysis; review 
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1. Introduction 
Prostate cancer (PCa) is the most frequently detected type of cancer in men and constitutes a 
major healthcare problem in developed countries [1], remaining the second most common cause of 
cancer-related death in the Western world [2]. 
Following initial diagnosis, the majority of men receive several treatments, such as usually a 
radical prostatectomy ± lymphadenectomy or radiation/brachytherapy in case of localized disease, 
and systemic therapy in case of widespread disease. Relapse remains common despite advances in 
primary treatment and improved overall survival (OS) with a biochemical recurrence developing in 
20% to 40% of patients [3–6]. 
The management of primary and recurrent PCa patients has been completely changed after the 
inclusion of new imaging modalities, such as magnetic resonance imaging (MRI) and positron 
emission tomography (PET). MRI is a well-documented method to evaluate the extension of the 
primary tumor and to detect and localize recurrent cancer within the prostate [7–9]. However, routine 
multiparametric (mp) MRI is still limited by its poor specificity to differentiate significantly from 
indolent PCa [10]. 
In the last 10 years, PET/computed tomography (PET/CT) has gained an important role in the 
evaluation of patients with PCa. Radiolabeled choline PET/CT has demonstrated the ability to detect 
the presence of early recurrence of disease when conventional imaging resulted negative [11]. 
Furthermore, the recent introduction of radiolabeled prostate specific membrane antigen (PSMA), 
like 68Ga-PSMA and 18F-PSMA, has significantly improved the detection rate, also in case of early 
recurrence of disease (such as a prostate-specific antigen (PSA) <0.5 ng/mL) [12]. 
Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-[18F]-FACBC) is an amino acid PET 
tracer that has shown to be promising for visualizing PCa. This tracer was developed for L-amino 
acid transport evaluation; it demonstrated favorable dosimetry with the liver being the critical organ 
[13]. Its safety, tracer stability, and uptake kinetics in patients have been reported in a phase I trial 
[14]. Nowadays, 18F-FACBC is approved by the Food and Drug Administration (FDA) and the 
European Commission (EC) to detect PCa in patients with elevated PSA following prior treatment. 
Approval was based on encouraging diagnostic performance and histologically confirmed data on 
patients with biochemical recurrence [15]. Recently it was included in the National Comprehensive 
Cancer National (NCCN) guidelines for the management of recurrent PCa patients. 
Until now, few pooled data have been published about the role of 18F -FACBC PET/CT in patients 
with PCa. Ren et al. [16] collected data from six studies, published between 2011 and 2014 and 
including 251 patients that concluded for a good sensitivity of 18F -FACBC PET/CT for the detection 
of PCa recurrence. In 2015, Yu et al. [17] published a critical analysis of the available tracers for 
PET/CT in PCa, collecting data for 18F -FACBC from five studies (n = 84 subjects), showing a limited 
detection rate of this imaging technique for the recurrence of post-prostatectomy PCa (detection rate 
= 40%). However, in May 2016, 18F -FACBC PET/CT received the approval by the Food and Drug 
administration for use in patients with suspected recurrent PCa [18]. In the last years, many 
prospective and retrospective experiences have been performed, and therefore, a new update of the 
recent findings seems necessary, not only in the restaging but also in the initial staging of disease. 
Therefore, the present review and meta-analysis aimed to investigate the diagnostic 
performance of 18F -FACBC in the detection of primary and recurrent PCa patients. 
2. Materials and Methods 
2.1. Search Strategy and Study Selection 
A bibliographic search until 30 April 2019 was performed by including the following databases: 
Pubmed, Scopus, Embase, Web of Science, Cochrane library, and Google Scholar. The terms used 
were “FACBC” or “fluciclovine” AND “prostate cancer” or “prostate” AND “PET” or “Positron 
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Emission Tomography”. The search was carried out with and without the addition of filters (such as 
English language only; type of article: original article, research article; subjects: humans only). Three 
reviewers (Domenico Albano, Viviana Frantelizzi and Matteo Baucknhet) performed the literature 
search, and two independent reviewers (Priscilla Guglielmo and Lorenzo Fantechi) selected the study 
inclusion and data extraction in duplicate. Any discrepancies were resolved by a consensus, when 
necessary. All recognized records were combined, and the full texts were retrieved. Full texts were 
further evaluated by four reviewers (Giovanni Argiroffi, Riccardo Laudicella, Pierpaolo Alongi and 
Laura Evangelista). Moreover, a search across the databases was completed by another reviewer 
(Anna Giulia Nappi) checking the references of the studies included to further improve the eligibility.  
This systematic review was carried out using established methods [19], and the presentation of 
results was made according to the PRISMA guidelines [20]. All studies that fulfilled the inclusion 
criteria were considered eligible for the systematic review and meta-analysis: (a) a sample size more 
than 10 patients; (b) the index test: 18F-FACBC PET/CT; (d) the outcomes, such as detection rate (DR), 
true positive (TP), true negative (TN), false positive (FP), and false negative (FN), which allowed us 
to construct 2 × 2 contingency tables. Moreover, in the case of studies that included the same 
population, the report with the highest number of enrolled patients was considered for the meta-
analysis. Conversely, reviews, clinical reports, meeting abstracts, and editor comments were 
excluded. The quality assessment included both the risk of bias assessment and applicability concerns 
by using QUADAS-2 evaluation [21]. 
2.2. Data Extraction 
For each included study, general information was retrieved, such as basic data (authors, journal, 
year of publication, country and study design), patient characteristics (number of patients, mean or 
median age, Gleason score), type of treatment, mean or median PSA value at PET time, and PSA 
kinetic values. 
2.3. Statistical Method 
StatsDirect and Meta-Analyst (version Beta 3.13; [22]) were used to carry out the analysis. 
Heterogeneity was tested using the χ2 and the I2 tests. The χ2 -test provided an estimate of the 
between-study variance and the I2 test measured the proportion of inconsistency in individual 
studies that cannot be explained by chance. According to Higgins et al. [19], the values of 25%, 50%, 
and 75% for heterogeneity (I2) were considered low, moderate, and high, respectively. In accordance 
with the recommendation of the Cochrane Oral Health Group, the meta-analysis was carried out with 
the random-effect model as the number of studies was equal or superior to 4.  
Data on diagnostic performance such as pooled sensitivity, pooled specificity, positive and 
negative likelihood ratio (LR+ and LR−), diagnostic odds ratio (DOR) with 95% confidence intervals 
(CIs) for the evaluation of primary and recurrent PCa, were assessed. A patient-based and a region-
based meta-analyses were carried out in accordance with available data. Publication bias was 
assessed using a funnel plot. A symmetrical plot was indicative of the absence of publication bias. 
3. Results 
3.1. Search Results 
The literature search revealed 40 articles published from 1 January 2007 to 30 April 2019. 
Reviewing titles and abstracts, we excluded 24 articles because these did not fit with the field of 
interest or because these papers were letters, editorials, reviews or due to the patient data overlap. 
Therefore, 15 studies were selected and included in the systematic reviews and 9 articles were 
considered for the meta-analysis (Figure 1). Also the papers by the developers of 18F-FACBC were 
considered [23,24]. 
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Figure 1. PRISMA flow-chart. 
3.2. Study Characteristics 
The basics characteristics of the included studies are reported in Table 1 [15,23–36]. The number 
of enrolled patients ranged from 15 to 596, and a total of 1226 PCa patients were included. The 
selected articles were published by researchers from Europe, USA, and Japan. Four studies were 
retrospective whereas 11 studies were prospective. 18F-FACBC PET/CT was performed in the 
preoperative setting in 6 studies (n = 178 patients), for the detection of recurrence in patients with 
biochemical relapse after primary treatments in 8 studies (n = 1033 patients) and in both settings in 1 
study (n = 15 patients). In the restaging, the mean value of PSA ranged between 0.44 and 17.94 ng/mL. 
The mean and median age of the patients ranged from 42 to 90 years. The Gleason score (GS) 
was ≤6 in 49 (4%) patients, 7 in 376 (30.6%) patients, ≥8 in 142 (11.6%) patients, not available in the 
remaining 659 (53.8%). No significant adverse effects after the administration of 18F-FACBC were 
reported. 
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Table 1. Characteristics of selected studies. 
Study Characteristics Patient Characteristics 
Authors Year  Journal Country Study Design Setting N. pts 
Mean 
Age 
(Range) 
Gleason 
Score (n) 
Type of Treatment (n) Mean PSA 
(Range) 
Mean PSA 
Doubling Time 
(Range) 
Schuster et al. 
[23] 
2007 JNM USA Prospective 
Staging (n 
= 9) 
Restaging 
(n = 6) 
15 
62y (45–
76) 
6 (2) 
7 (2) 
8 (2) 
9 (2) 
10 (1) 
NA (6) 
SP (1),  
BCT + RT + CTR (1),  
BCT (2),  
BCT + RT (1), 
RP + RT (1), 
naive (9)  
15 ng/mL 
(1.9–71) 
NA 
Schuster et al. 
[24] 
2011 Radiology USA Prospective Restaging 50 
68.3y 
(50–90) 
NA 
RP (13),  
CTR, HFUS, EBRT, and/or BCT 
(37) 
6.62 ng/mL 
(0.11–44.74) 
NA 
Turkbey et al. 
[25]  
2014 Radiology USA Prospective Staging 21 
62y (44–
73) 
6 (3) 
7 (12) 
8 (5)  
9 (1) 
RARP + LND (21) 
13.5 ng/mL 
(3.55–37.3) 
NA 
Kairemo et al. 
[26] 
2014 
BioMed Research 
Intern 
Finland Retrospective Restaging 26 * 
68.1y 
(56–77) 
5 (3) 
6 (7)  
7 (7) 
8 (3) 
9 (5) 
RP + RT (12), RT (13), 
ADT (20), BT (11), 
CHT(5), 153Sm-EDTMP (7), 
Denosumab (1) 
7.9 ng/mL 
(0.11–69) 
positive FACBC 
3.2mo (0.3–6) 
negative FACBC 
31.2mo (8–84)  
Nanni et al. 
[27] 
2014 
ClinGenitourin 
Cancer 
Italy Prospective Restaging 28 
67y  
(55–78) 
6 (1) 
7 (16) 
8 (6) 
9 (4) 
10 (1) 
RP (28),  
RT (11),  
ADT (14)  
2.9 ng/mL 
(0.2–14.6) 
NA 
Nanni et al. 
[28] 
2015 ClinNucl Med Italy Prospective  Restaging 50 
67y (55–
78) 
≤6 (4) 
7 (31) 
8–10 (15) 
RP (50), 
RT (23),  
ADT (21) 
3.2 ng/mL 
(0.24–15.6) 
NA 
Odewole et al. 
[29] 
2016 EJNMMI USA Retrospective Staging 53 
67.57y 
(49–90) 
7 (49) 
NA (4) 
RP (7), EBRT (5),  
BCT (6), CTR (4),  
HT (1), 2 or more treatment 
(30) 
7.2 ng/mL 
(0.11–44.8) 
18.6mo ## (−31.6–
357.8) 
 
Bach-Gansmo 
et al. [15] 
2017  J Urol 
Norway 
Italy USA 
Retrospective Restaging 596 
67y 
(42–90) 
6.7 (110) § 
7.4 (355) 
§§ 
 
RP (130), RP + other but no RT 
(62), 
RT (76), RT + other (266), 
other but no RT/RP (41) 
5.43 ng/mL 
(0.05–82.0) 
NA 
Akin-Akintayo 
et al. [30] 
2017 ClinNucl Med USA Prospective Restaging 42 
62y  
(42–75) 
7 (42) # RP (42) 
2.1 ng/mL 
(0.07–11.15) 
NA 
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Selnaes et al. 
[31] 
2018 EurRadiol Norway Prospective Staging 26 
66.2y 
(55–71.9) 
7 (11) 
8 (8) 
9 (7) 
RARP + LND (26)  
14.6 ng/mL  
(3.7–56.9) 
NA 
Jambor et al. 
[32] 
2018 EJNMMI Finland Prospective Staging 26 
65y **  
(49–76)  
6 (1) 
7 (17) 
8 (2) 
9 (6) 
RARP + LND (26) 
12 ng/mL 
(4.1–35) 
NA 
Akin-Akintayo 
et al. [33] 
2018 Eur J Radiol USA Prospective Staging 24 
70.8y 
(60–83) 
7 (24) # 
BCT (3), RT (3),  
PT (1), CTR (1), CTR + HT (1),  
BCT + other treatment but no 
RP (13),  
other treatment but no BCT (2) 
8.5 ng/mL 
(2.2–29.3) 
NA 
Andriole et al. 
[34] 
2019 J Urol USA Prospective Restaging 213 
66.4y  
(46–90) 
≤6 (27) 
7 (134) 
≥8 (50) 
NA (2) 
RP (121), RP + RT (43), 
EBRT (21), BCT (1), 
EBRT + BCT (2), EBRT + ADT 
(17), 
EBRT + CTR (2), CTR (1), 
BCT + ADT (1), EBRT + BCT + 
ADT (2), 
HIFU (1), High-dose BCT (1) 
4.24 ng/mL 
(0.2–93.5) 
NA 
England et al. 
[35] 
2019 Clin Nucl Med USA Retrospective Restaging 28 
67.1y  
(53–77) 
7 (19) 
8 (3) 
9 (6)  
Primary treatment 
RP (22), RP+ EBRT (3),  
RP + EBRT + ADT (1), EBRT + 
ADT (2) 
Salvage therapy 
RT (6), ADT (1), RT + ADT (1), 
LND (1) 
0.44 ng/mL 
(0.1–1.0) 
6.38mo 
(1.6–16.8) 
Suzuki et al. 
[36] 
2019 
Japanese J Clin 
Oncol 
Japan Prospective Staging 28 
67.9 (57–
77) 
<6 (1) 
7 (12) 
8 (8) 
9 (8) 
RARP + LND (28) 17.94 ng/mL 
(1.20–82.38) 
NA 
RP = radical prostatectomy; RS = radical surgery; EBRT = external beam radiotherapy; RT = radiotherapy; ADT = androgen deprivation therapy; LND = lymph nodal 
dissection; HT = hormone therapy; RARP = robot assisted radical prostatectomy; BT = bisphosphonate therapy; CHT = chemotherapy; BCT = brachitherapy; CTR = 
criotherapy; HFUS = high-frequency ultrasound; SP = subtotal prostatectomy; PT = proton therapy; NA = not-available. * 1/26 patient was affected by meningioma, 
considered as negative; ** Median value of the initial 32 patients; § Median Gleason-score value in Recurrent Prostate Cancer; §§ Median Gleason-score value in 
Primary Standard of Truth; # Median Gleason-score value; ## Only for 49/53 patients. 
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3.3. Methodological Quality 
All 15 studies were evaluated qualitatively using the QUADAS-2 tool (Table S1; Figure 2). The 
risk of bias was unclear for patient selection in 1 study, which did not provide information regarding 
consecutive enrollment [15]. For the index test and reference standard, the risk of bias was low in 6 
studies [24,29,31–33,36]. For flow and timing, many studies reported time intervals between PET/CT 
examinations and pathological or other imaging confirmations. The applicability of the included 
studies was adequate in the majority of reports, being unclear only in 1 study for the reference 
standard [30]. 
 
 
Figure 2. QUADAS 2 score of all included studies. 
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3.4. Qualitative Results 
PET/CT was employed in 14/15 studies, without CT contrast media injection, whereas PET/MRI 
was used in 2 studies [31,32]. The injected radiopharmaceutical activity and the time between 
radiotracer injection and image acquisition were similar across all studies. 
Analysis of PET images was mostly performed using visual analysis; however, additional semi-
quantitative criteria, i.e., maximal standardized uptake values (SUVmax), was performed in some 
reports [23,26–28]. 18F-FACBC PET/CT or PET/MRI identified the presence of PCa in prostatic and 
extra-prostatic bed, such as in the regional, distant lymph nodes and bone. The DR was available in 
9/15 studies. It ranged between 36% and 90%, being different in accordance with PSA serum levels 
(Table 2). Andriole et al. [34] demonstrated that DR was broadly proportional to pre-scan PSA: lesions 
were detected in 79% patients with PSA ≥ 1.0 ng/mL and in 84% with PSA ≥ 2.0 ng/mL. On the other 
side, some authors found that there was no statistically significant difference in the PSA values and 
PSA doubling-time (PSAdt) between patients with positive and negative findings [26,35]. England et 
al. [35] reported that the DR was significantly higher for patients with GS > 7 than those with a score 
equal to 7. 
The performance of 18F-FACBC PET/CT was different based on the phase and the site of PCa 
(Table 3). In particular, in the initial staging, the sensitivity for the primary and lymph nodes 
metastasis was 71% [32] and 67% [36], respectively. In the restaging setting, the sensitivity for the 
prostatic bed and extra-prostatic bed recurrence was 89% [24] and 90% [15], respectively. 
Interestingly, in the study by Turkbey et al. [25], 18F-FACBC uptake in tumors was similar to that in 
benign prostatic hyperplasia (BPH). However, Jambor et al. [32] reported that SUVmax in the primary 
tumor was statistically significantly higher for patients with GS > 7 than GS = 6 or BPH, thus 
underlying the importance of the patient selection. 
Akin-Akintayo et al. [33] compared 18F-FACBC PET/CT with mpMRI in patients with recurrent 
PCa showing a higher detection for the first modality (overall 94.7% vs. 36.8%); Turkbey et al. [25], 
instead, performed a sector-based comparison with histopathologic analysis in patients with a recent 
diagnosis of PCa, revealing lower sensitivity and specificity for 18F-FACBC PET/CT than for T2-
weighted imaging (67% and 66% vs. 73% and 79%, respectively), but combined modalities achieved 
a positive predictive value of 82% for tumor localization, which was higher than that with either 
modality alone. Another study proved higher positivity rates with 18F -FACBC PET/CT than 
enhanced CT at all PSA levels, PSAdt and GS in patients with suspected recurrent PCa [29]. 
Furthermore, the performance of 18F-FACBC PET/CT was superior to those of 111In-capromab 
SPECT/CT regarding sensitivity for prostatic and extra-prostatic bed (89% vs. 69% and 100% vs. 10%, 
respectively) [24]. Finally, two studies directly compared 18F-FACBC with 11C-Choline PET/CT, 
demonstrating a greater detection rate for 18F-FACBC than 11C-Choline, either on a patient- and a 
lesion-based analysis and despite the PSA serum levels [27,28].  
The change of management with 18F-FACBC PET/CT was reported by Andriole et al. [34], in 122 
out of 213 patients (56%); the most frequent change was to withhold planned salvage or non-curative 
systemic therapy in  favor of watchful waiting. Moreover, Akin-Akintayo et al. [30] demonstrated 
that 18F-FACBC PET/CT was able to modify the radiotherapy field and overall radiotherapy decision 
in 40.5% of patients with post-prostatectomy recurrent PCa. 
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Table 2. The selection of the studies. 
Author, (Ref) Year  Journal Country N pts Outcome DR TP TN FP FN 
Schuster et al. [23] 2007 JNM USA 9 Accuracy LN (patient-based) NA 2 5 0 2 
Schuster et al. [24] 2011 Radiology USA 50 
Accuracy (PB) FACBC (region-based) 
NA 
32 8 4 4 
Acc (extra-p) FACBC (region-based) 10 7 0 0 
Acc (PB) Capromab (region-based) 25 7 5 11 
Ac (extra-p) Capromab (region-based) 1 7 0 9 
Turkbey et al. [25] 2014 Radiology USA 21 
DR for primary 
19/21 (90%) 
    
Lesion-based 33 0 38 15 
Accuracy MRI (les-based) 34 0 21 14 
Kairemo et al. [26] 2014 BioMed Research Intern Finland 26 ** 
DR 
17/26 (65%) 
    
Patient-based 11 12 3 0 
Nanni et al. [27] 2014 ClinGenitourin Cancer Italy 28 DR (comparison with Choline) 10/28 (36%) NA NA NA NA 
Nanni et al. [28] 2015 ClinNucl Med Italy 50 DR (comparison with Choline) 17/50 (34%) NA NA NA NA 
Odewole et al. [29] 2016 EJNMMI USA 53 
DR (all PSA levels and clinical data) 
41/53 (77.4%) 
    
Accuracy (PB) FACBC 31 9 7 4 
Accuracy (PB) CT 4 14 2 31 
Accuracy (extra-pr) FACBC 12 15 0 15 
Accuracy (extra-pr) CT 3 15 0 23 
Bach-Gasmo et al. [15] 2017  J Urol 
Norway 
Italy 
USA 
596 
DR 
403/595 (67.7%) 
    
Lesion-based 153 216 93 91 
Region-based (PB) 74 14 20 10 
Region-based (Extra-prost) 36 1 3 4 
Patient-based 98 14 21 10 
Akin-Akintayo et al. [30] 2017 ClinNucl Med USA 42 DR (change in radiotherapy strategy) 34/42 (81%) NA NA NA NA 
Selnaes et al. [31] 2018 EurRadiol Norway 26 
Accuracy for LN NA     
Patient-based NA 4 16 0 6 
Region-based NA 6 185 0 14 
Jambor et al. [32] 2018 EJNMMI Finland 26 
Accuracy LN 
NA 
    
Patient-based 7 19 0 0 
Region-based NA NA NA NA 
Akin-Akintayo et al. [33] 2018 Eur J Radiol USA 24 
Accuracy (PB) FACBC * 
NA 
13 1 8 0 
Accuracy (PB) MRI * 5 5 4 8 
Accuracy (extra-p) FACBC 7 9 1 1 
Accuracy (extra-p) MRI * 4 7 3 4 
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Andriole et al. [34] 2019 J Urol USA 213 DR (also for PSA level) 122/213 (57%) NA NA NA NA 
England et al. [35] 2019 ClinNucl Med USA 28 DR (for site and clinical data) 13/28 (46%) NA NA NA NA 
Suzuki et al. [36] 2019 Japanese J ClinOncol Japan 28 
Accuracy LN 
NA 
    
Patient-based 4 19 3 2 
Lesion-based 4 28 5 3 
DR = detection rate; NA = not available; LN = lymph node; PB = prostatic bed; * M1 reader; ** 1/26 patient affected by meningioma was considered as negative. 
Table 3. Accuracies based on the study setting and the type of analysis. 
Type of Analysis Study Name (Year), Ref Setting (Site) TP FN TN FP Sensitivity Specificity 
Patient-based analysis 
Suzuki et al. (2019), [36] Staging (LN) 4 2 19 3 66.6% 86.3% 
Selnaes et al. (2018), [31] Staging (LN) 4 6 16 0 45% 80.8% 
Jambor et al. (2018), [32] Staging (primary) 7 0 19 0 70.6% 82.8% 
Bach-Gasmo et al. (2017), [15] Restaging (all) 98 10 14 21 90.7% 40% 
Kairemo et al. (2014), [26] Restaging (all) 11 0 12 3 76.2% 68% 
Schuster et al. (2007), [23] Staging/restaging (all) 2 2 5 0 50% 66.7% 
Region-based analysis (PB) 
Schuster et al. (2011), [24] Restaging 32 4 8 4 88.9% 66.7% 
Bach-Gasmo et al. (2017), [15] Restaging 74 10 14 20 88.1% 41.2% 
Akin-Akintayo et al. (2018), [33] Staging  13 0 1 8 78.3% 31.6% 
Odewole et al. (2016), [29] Staging 31 4 9 7 88.6% 56.3% 
Region-based analysis (extra-PB) 
Schuster et al. (2011), [24] Restaging 10 0 7 0 75% 70.6% 
Bach-Gasmo et al. (2017), [15] Restaging 36 4 1 3 90% 25% 
Akin-Akintayo et al. (2018), [33] Staging 7 1 9 1 87.5% 90% 
Odewole et al. (2016), [29] Staging 12 15 15 0 45.9% 80% 
LN = lymph node; TP = true positive; FN = false negative; TN = true negative; FP = false positive. 
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3.5. Quantitative Results 
In accordance with the inclusion criteria, the quantitative assessment was available in 9 studies 
[15,23,24,26,29,31–33,36] (Table 4). At patient-based analysis (n = 6 studies), the pooled sensitivity and 
specificity of 18F-FACBC PET/CT scan for the assessment of primary and recurrent PCa were 86.3% 
(95% CIs: 79.6–91.4%) and 75.9% (66.9–83.5%) with an heterogeneity of 78.6% and 88.7% (both p 
<0.0001), respectively. Moreover, the pooled DOR value was 16.453 (95% CI: 5.241–51.646), with 
heterogeneity of 30%. At the regional based-analysis (n = 4 studies), the pooled sensitivity of 18F-
FACBC PET/CT for the evaluation of primary and recurrent disease in the prostatic bed was higher 
than that in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled 
specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, 
respectively). Furthermore, LR+ was high in the extra-prostatic region, while LR- was low in prostatic 
bed, with heterogeneity of 0%. No asymmetry in the forest plot was found; therefore, no publication 
bias was present across the studies. 
Table 4. The pooled diagnostic performance for 18F-FACBC (independently from the clinical setting 
and site). 
Meta-Analysis 
Results  
Patient-Based Analysis (95% CI) 
Region-Based Analysis (PB) 
(95% CI) 
Region-Based Analysis (ex-
PB) (95% CI) 
Value I2 Value I2 Value I2 
Pooled 
sensitivity, % 
86.3% (79.6–91.4%) 78.6% 90.4% (84.8–94.4%) 22.1% 76.5% (66–85%) 87.3% 
Pooled 
specificity, % 
75.9% (66.9–83.5%) 88.7% 45.1% (33.2–57.3%) 63.3% 88.9% (73.9–96.9%) 78.7% 
DOR 
16.453  
(5.241–51.646) 
29.9% 
8.026 (3.841–
16.769) 
3.5% 
24.820 (3.777–
163.12) 
36% 
LR+ 4.557 (1.685–12.324) 72.9% 1.598 (1.088–2.349) 70% 6.024 (0.568–63.943) 85.6% 
LR− 0.337 (0.166–0.681) 63.6% 0.221 (0.130–0.375) 0% 0.251 (0.058–1.090) 71.6% 
PB = prostatic bed; PPV = positive predictive value; NPV = negative predictive value; DOR = 
diagnostic odds ratio; LR = likelihood ratio; IC = interval of confidence; I2 = inconsistency. 
4. Discussion 
As previously mentioned, the meta-analysis from Ren et al. [16] reported that 18F-FACBC 
PET/CT had a high sensitivity (pooled sensitivity = 87%) and a moderate specificity (pooled 
specificity = 66%), therefore it can be considered an useful non-invasive, metabolic imaging technique 
for the diagnostic workup of PCa relapse. In the present meta-analysis, performed in 1226 PCa, the 
pooled sensitivity and specificity were 86% and 76% respectively, thus showing a slight increase for 
the specificity. 
Furthermore, in the analysis by Yu et al. [17], FACBC showed a detection rate ranged between 
22% and 61% for prostatic disease and between 19% and 33% for extra-prostatic disease, in 
accordance with the primary treatments (radical prostatectomy or radiotherapy). In our meta-
analysis, we did not evaluate the pooled detection rate, but we calculated the pooled sensitivity and 
specificity. As illustrated in Table 4, the sensitivity of 18F-FACBC was equal to 90% for the 
identification of disease in the prostatic bed and 77% for extra-prostatic organs. 
However, in the last years, PSMA-PET has rapidly been introduced in clinical practice for the 
management of patients with recurrent PCa, particularly in case of low PSA levels [37]. Already, the 
study by Yu C-Y et al. [17] reported that 18F-FACBC, Choline and Acetate-PET have similar detection 
rate for overall site of disease after radical prostatectomy or radiotherapy (ranged between 40% and 
81%), but PSMA was able to reach a detection rate ranged between 82% and 96% in the same setting. 
Two recent papers about a head-to-head comparison between 18F-FACBC and 68Ga-PSMA 
PET/CT have been published. The data are controversial. In the study by Pernthaler et al. [38] 
involving 58 patients with recurrent PCa with a PSA level ranged between 0.2 and 230 ng/mL, 18F-
FACBC detected more accurately the presence of a local recurrence than 68Ga-PSMA, due to its 
favorable biodistribution. Furthermore, the authors found that 18F-FACBC is almost equivalent to 
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68Ga-PSMA-11 in detecting distant metastases of PCa recurrence. Conversely, in the study by Calais 
et al. [39] enrolling 50 patients with recurrent PCa, the detection rate of PSMA-PET was significantly 
higher than 18F-FACBC (56% vs. 26%, respectively) in case of a PSA level <1 ng/mL. However, the 
authors found that the detection rate for the local recurrence was higher for 18F-FACBC than 68Ga-
PSMA PET/CT (38% vs. 14%, respectively). The missing data about the diagnostic performance, in 
terms of sensitivity and specificity in both the above-mentioned papers, represent a great limitation 
for the final conclusion on “the best radiopharmaceutical agent”. A recent paper by Lawhn-Heath et 
al. [40] reported that the sensitivity and specificity of 68Ga-PSMA-11 for recurrent PCa are equal to 
89.1% and 31.2%, thus registering a high rate of false positivity. 
From the present systematic review and meta-analysis arise some considerations:  
1. 18F-FACBC is more performant than 111In-capromab SPECT/CT and 11C-Choline for the detection 
of PCa recurrence. Therefore, if available it should be preferred in patients with a PSA increase, 
after primary treatments. However, data about the comparison with 18F-Choline PET/CT are 
missing and should be explored, also considering the radioisotope properties.  
2. The combination of 18F-FACBC PET/CT with mpMRI (or with a PET/MRI) seems useful for the 
detection of primary PCa, and therefore, it would be suggested in case of undetectable tumors 
in patients with a negative biopsy but a persistent PSA level increase. However, the 
interpretation of this sophisticated imaging required a great experience and a significant 
learning curve. 
3. The sensitivity for the evaluation of lymph node metastasis in the initial staging of disease is 
moderate (45%–66%; [31,36]), like for the other radiopharmaceuticals (radiolabeled PSMA and 
Choline; [41,42]). Probably the recent introduction of new imaging modalities, such as digital 
PET/CT or PET/MRI that has a higher spatial resolution, would improve the pathological lymph 
node detection. 
4. The pooled sensitivity for the identification of recurrence in prostate bed is high, being >90% 
with a limited pooled specificity (about 45%), probably due to the FP findings in case of inflamed 
cells, as reported by Oka et al. [43]. However, the absent uptake of radiopharmaceutical in the 
bladder represents a great advantage for the identification of peri-anastomotic PCa recurrence. 
Further data about the complementary role of 18F-FACBC and MRI are required for the 
assessment of prostatic bed recurrence, at different PSA levels. 
5. The recurrence in the extra-prostatic site may be assessed by 18F-FACBC PET/CT with a moderate 
sensitivity and specificity, independently from the PSA levels. However, the correlation with 
PSA kinetics is warranted in a selected large cohort of patients, thus testing the final impact on 
the patient management. 
6. Despite some articles have defined a potential impact of 18F-FACBC PET/CT on therapeutic 
management, there is still a lack information with regard to its role in radiotherapy planning 
and other adapted therapy. 
5. Future Researches 
More data about the correlation between the detection rate of 18F-FACBC PET/CT or PET/MRI 
and the PSA kinetics are warranted, particularly by a site and lesion-based analysis. The 
complementary role of 18F-FACBC PET/CT and mpMRI for the evaluation of the prostatic bed should 
be largely explored. A head-to-head comparison with 18F-Choline would be used in order to definitely 
assess its advantages in clinical routine. Data about the utility of 18F-FACBC PET/CT in patients 
undergoing or not hormonal therapy are required. The evaluation of response to therapy 
(chemotherapy or new hormonal agents) by 18F-FACBC PET/CT should be assessed. Finally, 
additional data about the effect of 18F-FACBC PET/CT on patient management is required, by 
considering both PSA levels and histopathological PCa characteristics. 
6. Conclusions 
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18F-FACBC PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of 
the prostatic bed. However, additional studies are mandatory in order to evaluate its utility in clinical 
routine. 
Supplemental Materials: The following are available online at www.mdpi.com/xxx/s1, Table S1: QUADAS 2 
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Figure S1: Forest-plots for the patient-based and region-based analysis. Figure S2: ROC curves for patient-based 
and region-based analyses. 
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